4.48
-0.15
(-3.24%)
May 17 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 4.34 - 4.63 |
| 52 week | 3.82 - 8.88 |
| Open | 4.63 |
| Vol / Avg. | 84,283.00/73,897.00 |
| Mkt cap | 67.92M |
| P/E | - |
| Div/yield | - |
| EPS | -1.58 |
| Shares | 15.16M |
| Beta | 0.46 |
| Inst. own | 57% |
Events
Aug 12, 2013
Q2 2013 PDI, Inc. Earnings Release
May 14, 2013
Q1 2013 PDI, Inc. Earnings Conference Call -
May 13, 2013
Q1 2013 PDI, Inc. Earnings Release
Mar 20, 2013
PDI, Inc. presentation at the ROTH Capital Partners 25th Annual Growth Stock Conference -
Mar 7, 2013
Q4 2012 PDI, Inc. Earnings Conference Call -
Mar 6, 2013
Q4 2012 PDI, Inc. Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | 5.08% | -20.07% |
| Operating margin | 5.25% | -19.88% |
| EBITD margin | - | 1.52% |
| Return on average assets | 10.85% | -26.55% |
| Return on average equity | 23.79% | -53.53% |
| Employees | 882 | - |
| Carbon Disclosure Rating | - | - |
Address
Morris Corporate Center 1 Building A, 300 Interpace Parkway
PARSIPPANY, NJ 07054
United States - Map
+1-862-2077800 (Phone)
+1-302-6745266 (Fax)
PARSIPPANY, NJ 07054
United States - Map
+1-862-2077800 (Phone)
+1-302-6745266 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
PDI, Inc. provides outsourced commercial services to established and emerging pharmaceutical, biotechnology and healthcare companies in the United States. The Company is a provider of outsourced sales teams that focus on healthcare providers, offering a range of complementary sales support services designed to achieve its customers' strategic and financial product objectives. In addition to outsourced sales teams, it also provides other promotional services, including clinical educator services, digital communications, teledetailing and with the formation of its new business unit on August 1, 2011, Interpace BioPharma, provides pharmaceutical, biotechnology, medical device and diagnostics clients with full-service product commercialization solutions. It has three segments: Sales Services; Marketing Services and Product Commercialization Services (PC Services). On March 3, 2011, it announced the launch of a new business unit within its Sales Services segment, EngageCE.
Officers and directors
| Gerald P. Belle | Independent Chairman of the Board | |
| Nancy S. Lurker | Chief Executive Officer, Director | |
| Jeffrey E. Smith | Chief Financial Officer, Executive Vice President, Treasurer | |
| Gerald R. Melillo Jr. | President - Sales Services | |
| Jo Ann Saitta | Chief Information Officer, General Manager of Group DCA, LLC | |
| John Federspiel | Independent Director | |
| Veronica A. Lubatkin CPA | Independent Director | |
| Jack E. Stover | Independent Director | |
| Stephen J. Sullivan | Independent Director |